Rejuvenate Bio shrinks staff, pipeline focus as George Church spinout eyes 2024 gene therapy IND
Like many other biotechs in this market environment, small gene therapy maker Rejuvenate Bio has struggled to rejuvenate its bank account.
The San Diego startup, born out of George Church’s lab and the Wyss Institute, has laid off a sizable portion of its workforce and slimmed down its pipeline activity after struggling with funding, according to LinkedIn posts. Workers at the biotech, focused on aging-related diseases for both humans and dogs, posted in recent days to say the layoffs affected at least half of the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
